Skip to main content
Premium Trial:

Request an Annual Quote

Twist Bioscience, Regeneron Genetics Center Codevelop NGS Genotyping Panel for Population Sequencing

NEW YORK – Twist Bioscience and Regeneron Pharmaceuticals subsidiary Regeneron Genetics Center said on Monday that they have collaborated to develop a custom next-generation sequencing genotyping assay for population genetics.

Under the agreement, Twist will market the Diversity SNP Panel and make it available to customers worldwide.

Financial and other terms of the agreement were not disclosed.

Regeneron began using the custom NGS SNP panel in late 2020, John Overton, VP and chief sequencing officer, said in a statement. The panel includes approximately 1.4 million SNPs from a globally representative population.

In January, Twist revealed it is helping Regeneron convert from SNP microarrays to NGS-based genotyping with Twist's hybridization-based target capture panels. Twist has done at least $9 million in business with the pharma company.

The Scan

And a Fourth?

A fourth dose of the Pfizer-BioNTech SARS-CoV-2 vaccine in an Israeli study increased antibody levels but did not prevent Omicron variant infections, according to the Financial Times.

For Better Science Software

A virtual institute funded by former Google CEO Eric Schmidt's philanthropy aims to lure software engineers to academia, Science reports.

Recommendation Explanations

The New York Times writes that the US Centers for Disease Control and Prevention is straining to both make and explain decisions based on limited information.

Genome Research Papers on De Novo Mutation Rates, Polyploid Genotyping, Oncogene Epigenomic Translocation

In Genome Research this week: de novo mutations rates in hemoglobin subunits, analysis of variant calling methods for polyploid plants, and more.